Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir

Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings

Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome

Adocia and Tonghua Dongbao report positive Phase 3 results for ultra-rapid insulin BioChaperone Lispro in Type 1 diabetes

Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress

Privo Technologies reports progress in oral cancer trial

Astellas to present VEOZAH (fezolinetant) data at Menopause Society 2025 Annual Meeting

First patient in the Nordics treated with BioArctic and Eisai's Leqembi for early Alzheimer's disease

Imaging Biometrics acquires Kirkstall to expand presence in advanced cell culture technologies

Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference

EiIean Therapeutics to present data on novel wild-type sparing, reversible pan-EGFR inhibitor ZE77-0273

BioArctic and Eisai's Leqembi Iqlik (lecanemab-irmb) selected as one of TIME's best innovations of 2025

BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL

Biophytis and Asian consortium to fund first Phase 3 trial in sarcopenia

Aptamer Group secures GBP112,000 contract with top 10 global pharmaceutical company